To date, OWS has spent a lot on vaccine candidates and very little on therapeutics. I understand (albeit secondhand from someone on the margins of west wing) that they have now been ordered to shift attention to therapeutics so that the current administration has a chance to claim "good Coronavirus news" before the election. I mean, it makes sense to me.

Quote:

---

In case you haven't been following the news, OWS is in deep shit with the Congressional Subcommittee on Coronavirus, which is a subcommittee of the of the House Oversight Committee. They are being investigated and a very intimidating letter was sent out by Clyburn. I believe someone posted it here.

I have no trouble believing the letter is quite new, as OWS is under a ton of pressure to show they haven't played favorites with companies that Moncef Slaoui has been CEO/boardmember/major shareholder of (notably GSK and Moderna) I bet they did outreach to small companies with promising therapies very quickly, so they can cover their favoritism and corruption.

I doubt CYDY was the only company they reached out to. Not sure why this matters though. It doesn't change that CYDY was one of the companies.

I would believe that OWS is ready to write checks because they are in trouble.

Read More: https://investorshangout.com/post/view?id=586...z6VnUkr9aR

---